RESUMEN

A large number of studies suggest that growth hormone (GH) modulates immune cell number and function. For example, GH administration in vitro or in animal models enhances antibody synthesis, increases T-lymphocyte proliferation, augments cytotoxic activity of natural killer cells, up-regulates priming of peritoneal and alveolar macrophages, and increases survival rates after infectious challenge. Similar effects on immune cells have been observed with insulinlike growth factor I (IGF-I), a major mediator of GH's anabolic actions. In critically ill patients, the administration of recombinant human GH improves nitrogen and mineral retention, enhances protein synthesis, and reduces urea generation. However, only limited data are available on the modulation of immune function and infection rates with GH treatment in catabolic patients. Limited studies in burn patients have shown improved wound healing and shortened hospital stay with GH therapy. Growth hormone was recently shown to improve cell-mediated immune responses and to maintain serum immunoglobulin concentrations after abdominal surgery in clinically stable patients. The immunomodulatory effects of GH administration may potentially limit septic complications in the intensive care unit setting. However, controlled studies in well-defined patient groups are needed to evaluate the potential beneficial effects of GH on immune function and infection risk in critically ill patients.

Asunto(s)

RESUMEN

Microdilution antimicrobial susceptibility testing was performed with 73 isolates of Pseudomonas cepacia collected from the sputum of patients throughout Michigan with cystic fibrosis. Susceptibility testing was done using new and investigational antibiotics (loracarbef, cefixime, cefpirome, desacetyl-cefotaxime, cefpodoxime, cefmetazole, cefepime, cefprozil, and fleroxacin) and commonly used antibiotics (ceftazidime, mezlocillin, piperacillin, ciprofloxacin, tobramycin, and amikacin). Ceftazidime was the most active antibiotic, and 91.8% of isolates were susceptible to it with MIC50 and MIC90 values of < or = 4 and 16 micrograms/ml, respectively. For mezlocillin, piperacillin, and ciprofloxacin 84.9, 89 and 39.7% of the isolates, respectively, were mostly moderately susceptible. Loracarbef, cefixime, cefprozil, cefmetazole, cefepime, fleroxacin, cefpodoxime, tobramycin, and amikacin did not show activity against P. cepacia. For cefpirome and desacetylcefotaxime 24.7 and 60.3% of the isolates, respectively, were moderately susceptible. Both MIC50 and MIC90 were > 32 micrograms/ml for cefpirome and 32 and > 64 micrograms/ml for desacetylcefotaxime.

Asunto(s)

Asunto(s)

Asunto(s)

RESUMEN

The extended-spectrum penicillins have a similar spectrum of activity and clinical efficacy. The newer acylaminopenicillins (azlocillin, mezlocillin, piperacillin) offer several potential therapeutic advantages over the carboxypenicillins (carbenicillin, ticarcillin), but they are more expensive per gram. Literature reviews of these penicillins suggest that individual hospital susceptibility patterns and cost should guide selection of the most appropriate antibiotic for formulary addition. Consequently, the authors performed a microbiologic, utilization, and cost review of these antibiotics in a community hospital. From this hospital and literature review, the authors were able to make the following conclusions: (1) the newer acylaminopenicillins exhibited similar activity against common clinical pathogens and were microbiologically more active than the carboxypenicillins; (2) none of these antibiotics used alone appears adequate for empiric treatment of serious systemic gram-negative bacillary infections; (3) the extended-spectrum penicillins were prescribed in a similar fashion and usually in conjunction with an aminoglycoside; and (4) significant cost savings can be realized when less expensive drugs are used. The authors found only minor differences in microbiologic activity and clinical use among the newer extended-spectrum penicillins. Therefore, they recommend the least expensive drug for routine use in the hospital.

Asunto(s)

Asunto(s)

RESUMEN

We reviewed the records of 23 pediatric patients who had received at least one central venous catheter during a two-year period. Nine patients had acute lymphoblastic leukemia (ALL), nine had other hematologic/oncologic diagnoses, and five had cystic fibrosis. Twenty-nine of 65 febrile episodes in 16 patients were associated with a catheter-related infection. Twenty of 40 catheters were associated with an infection over a period of 7,229 catheter days. For every 1,000 catheter days, four episodes of infections were observed. The number of infections/1,000 catheter days, the average life of a catheter (approximately equal to 180 days), and mean number of days elapsing before the first infection were not significantly different in the three diagnostic groups. Broviac catheters were used most often (24/40), followed by Quinton (9/40) and Port-a-Cath (7/40). Broviac catheters lasted twice as long (224 days, p less than 0.01) as Quinton and Port-a-Cath. Gram-positive cocci were isolated most frequently and Staphylococcus epidermidis was the most common pathogen. No consistent relationship between an absolute neutrophil count of less than 1,000/mm3 and infection with gram-positive cocci was seen. However, seven of eight episodes of gram-negative bacillary infections occurred in patients with an absolute neutrophil count of less than 1,000/m3 (p less than 0.005). Those patients who were not considered terminally ill responded well to antimicrobials. Catheter removal was necessary in only two instances.

Asunto(s)

RESUMEN

A case of multiple splenic aspergillomas (mycetomas) without systemic involvement is a patient with acute lymphoblastic leukemia is described. The patient underwent splenectomy without concomitant antifungal therapy. There has been no recurrence of the disease for over two years. Granulocytopenia and airborn contamination may have played a role in the acquisition of this disease. The value of serology, radionuclide scans and cultures in the diagnosis of Aspergillus infections is explored. The role of granulocyte transfusions, antifungal chemotherapy and the achievement of bone marrow remission in localization of the fungal disease is discussed.

Asunto(s)

Asunto(s)